NRP/563 Week 7: Menopause and Midlife Health, sample paper

Five Bladder Infections in Two Years and Pain She Had Stopped Mentioning: Genitourinary Syndrome of Menopause in a 63-Year-Old and the Vaginal Estrogen That Treats Both

[Student Name]

University of Phoenix

NRP/563: Management of Women's Health Issues

Week 7 Assignment

[Instructor Name]

[Date]

The patient is a composite written for a model paper.

Mrs. B., a 63-year-old retired bank manager, comes after her fifth urinary tract infection in two years, each treated with antibiotics. When I ask about vaginal symptoms, she hesitates, then says intercourse has been painful for several years and she and her husband "have mostly stopped." She also has vaginal dryness and burning. Her last menstrual period was at 51. She took no hormone therapy. This paper explains how these problems are connected and treated.

Naming the Condition

Portman and Gass (2014) proposed the term genitourinary syndrome of menopause to describe the symptoms and signs of estrogen deficiency affecting the labia, vagina, urethra and bladder, including dryness, burning, irritation, lack of lubrication, painful intercourse and urinary urgency, dysuria and recurrent urinary tract infections. The term replaced vulvovaginal atrophy to include urinary symptoms and to use language women find acceptable.

The Mechanism

Estrogen maintains the thickness, elasticity and blood flow of vaginal and urethral tissues and supports glycogen-rich epithelial cells. Lactobacilli convert glycogen to lactic acid, keeping vaginal pH low, which inhibits growth of bacteria from the bowel that cause urinary infections. After menopause, the epithelium thins, glycogen falls, lactobacilli decline and pH rises, allowing colonization by uropathogens and making the tissue fragile and painful.

Examination

The vulvar and vaginal tissues are pale, thin and dry, with loss of folds and small petechiae. Vaginal pH is 6.0. The urethral meatus is prominent and slightly red. No masses or lesions.

Her bladder infections and her painful intercourse were two ends of the same thin, dry tissue.

Evidence for Preventing Infections

Raz and Stamm (1993) randomly assigned postmenopausal women with recurrent urinary tract infections to intravaginal estriol or placebo. The infection rate fell to 0.5 episodes per patient-year with estriol compared with 5.9 with placebo. Lactobacilli reappeared in 61% of treated women and in none of the placebo group, and vaginal pH fell from 5.5 to 3.8, showing that restoring estrogen restored the protective flora.

The Treatment

The North American Menopause Society's position statement recommends low-dose vaginal estrogen as effective treatment for genitourinary syndrome of menopause and notes that nonhormonal moisturizers and lubricants are first-line for mild symptoms (North American Menopause Society, 2020). For Mrs. B., with moderate symptoms and recurrent infections, I prescribe vaginal estradiol cream, 0.5 g nightly for two weeks, then twice weekly. Alternatives include a vaginal estradiol tablet, insert or ring.

Safety Concerns

Mrs. B. worries about breast cancer and clots because of news about hormone therapy. I explain that systemic hormone therapy, pills or patches, differs from low-dose vaginal estrogen, which has minimal absorption into the bloodstream, and that the NAMS statement supports its use without a progestogen for endometrial protection in most women (North American Menopause Society, 2020). She has no history of breast cancer or clots. For women with a history of breast cancer, decisions are individualized with the oncologist.

Why Systemic Hormones Are Not Needed

Systemic hormone therapy treats hot flashes and can improve genitourinary symptoms, but Mrs. B. no longer has hot flashes, and her symptoms are local. Low-dose vaginal therapy treats the tissue that needs it with far less exposure, which the NAMS statement supports as the preferred approach when symptoms are limited to the genitourinary tract (North American Menopause Society, 2020).

What to Expect

Improvement in dryness and pain often begins within a few weeks, with full benefit after about three months. Urinary infection prevention may take longer to become evident, as flora are restored. Mild vaginal discharge or breast tenderness can occur at first. She should report any vaginal bleeding, which in a postmenopausal woman always needs evaluation.

Why These Symptoms Go Unmentioned

Genitourinary symptoms are common after menopause, yet many women never raise them, believing they are an inevitable part of aging or feeling embarrassed. Mrs. B. had stopped mentioning her pain years ago. Asking directly at every midlife visit, as I did here, is often the only way the problem is found.

Lubricants and Moisturizers

In addition, I recommend a water- or silicone-based lubricant during intercourse and a vaginal moisturizer used two to three times a week, which improve comfort while estrogen takes effect over several weeks.

Sexual Health

I ask whether she would like to talk about sexual health with her husband present at a future visit. Pain often leads to avoidance, tension and loss of desire; addressing the pain may restore intimacy, and pelvic floor physical therapy can help if muscle guarding persists.

Urinary Infection Plan

Future urinary symptoms should be confirmed with a urine culture before antibiotics, since not all urinary symptoms in genitourinary syndrome are infections. If infections continue despite estrogen, other preventive options can be considered.

Other Prevention Measures

Alongside estrogen, general measures can reduce urinary infections: adequate fluid intake, urinating after intercourse and avoiding spermicides. Cranberry products have mixed evidence; she may try them if she wishes, but they are not a substitute for treating the underlying tissue change.

Pelvic Floor Health

Some women with long-standing painful intercourse develop involuntary tightening of the pelvic floor muscles, which can persist after the tissue heals. If pain continues after three months of estrogen, I will refer her to a pelvic floor physical therapist, who can teach relaxation and use gentle dilators to restore comfort.

Her Husband

Her husband may worry that he caused her pain. With her permission, including him in a future conversation can ease tension and support gradual return to intimacy at her pace.

Bone and Heart Health

Menopause also affects bones and cardiovascular risk. Her bone density scan is due, and her blood pressure and lipids are reviewed at this visit as part of midlife care.

Cost and Access

Vaginal estrogen products vary in cost, and some are expensive without insurance. I check her plan's formulary and choose the covered cream, noting that generic estradiol tablets are an alternative if cost changes.

If She Develops Bleeding

Any postmenopausal bleeding while on vaginal estrogen needs evaluation to rule out endometrial problems, even though low-dose vaginal therapy rarely stimulates the endometrium.

Reassurance About Aging

Mrs. B. said she thought painful sex was simply part of getting older. I explained that it is common but treatable, and that most women who use vaginal estrogen notice meaningful improvement.

Documenting Symptoms

I record her symptoms using her words and a simple severity scale, which lets us measure improvement at follow-up rather than relying on memory.

Follow-Up

I will see her in three months to review symptoms, infections and adherence.

Conclusion

Mrs. B.'s recurrent urinary infections and painful intercourse share a cause: estrogen loss thinning the genitourinary tissues and shifting the vaginal flora. A randomized trial showed vaginal estriol cut recurrent infections dramatically by restoring lactobacilli, and the NAMS position statement supports low-dose vaginal estrogen as effective and safe for most women. Treatment, lubricants and open discussion of sexual health address both problems with one plan.

References

North American Menopause Society. (2020). The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause, 27(9), 976-992. https://doi.org/10.1097/GME.0000000000001609

Portman, D. J., & Gass, M. L. S. (2014). Genitourinary syndrome of menopause: New terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society. Menopause, 21(10), 1063-1068. https://doi.org/10.1097/gme.0000000000000329

Raz, R., & Stamm, W. E. (1993). A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. New England Journal of Medicine, 329(11), 753-756. https://doi.org/10.1056/NEJM199309093291102